Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis

Respirology

Volumn 17, Issue 3, 2012, Pages 467-477

  Homma, Sakae ^a   Azuma, Arata ^b   Taniguchi, Hiroyuki ^c   Ogura, Takashi ^d   Mochiduki, Yoshiro ^e   Sugiyama, Yukihiko ^f   Nakata, Koichiro ^b   Yoshimura, Kunihiko ^b   Takeuchi, Masahiro ^b   Kudoh, Shoji ^b   Mochizuki, Y ^e   Munakata, M ^g   Nukiwa, T ^h   Ishii, Y ⁱ   Oritsu, M ^j   Yoshizawa, Y ^k   Takizawa, H ^l   Ohta, K ^l   Suzuki, E ^m   Chida, K ⁿ   Inoue, Y ^o   Kohno, N ^p   Nishioka, Y ^q   Hamada, H ^r   Kohno, S ^s   Suga, M ^t   Taguchi, Y ^u   Noma, S ^u   Takahashi, H ^v   Kanazawa, M ^w   Sakai, F ^x   Tomii, K ^y   Tomioka, Y ^z   more..

^a TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c TOSEI GENERAL HOSPITAL   (Japan)

^d Kanagawa Prefectural Cardiovascular and Respiratory Center Hospital   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION HIMEJI MEDICAL CENTER   (Japan)

^f JICHI MEDICAL UNIVERSITY   (Japan)

^g FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^h TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ DOKKYO MEDICAL UNIVERSITY   (Japan)

^j JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^k TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^l TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m NIIGATA UNIVERSITY   (Japan)

ⁿ HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^o NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^p HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^q UNIVERSITY OF TOKUSHIMA   (Japan)

^r EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^s NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^t SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

^u TENRI HOSPITAL   (Japan)

^v SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^w SAITAMA MEDICAL UNIVERSITY   (Japan)

^x SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^y KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^z KOBE CITY MEDICAL CENTER WEST HOSPITAL   (Japan)

more..

Author keywords

Idiopathic pulmonary fibrosis; Inhaled N acetylcysteine; Monotherapy; Oxidant antioxidant imbalance; Randomized controlled trial

Indexed keywords

ACETYLCYSTEINE; CARBON MONOXIDE;

ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL ASSESSMENT; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXPLORATORY RESEARCH; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HOME NEBULIZER; HUMAN; HYPERCHOLESTEROLEMIA; JAPAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SORE THROAT;

EID: 84906292261     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2012.02132.x     Document Type: Article

References (37)

1. American Thoracic Society/European Respiratory Society. American Thoracic Society/European Respiratory Society International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2002; 165: 277-304.
2. Hunninghake GW,. Antioxidant therapy for idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353: 2285-7.
3. Cantin AM, Hubbard RC, Cystal RG,. Glutathione deficiency in the epithelial lining fluid of the lower respiratory in idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 1989; 139: 370-2.
4. Borok Z, Buhl R, Grimes GJ, et al,. Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet 1991; 338: 215-16.
5. Glissen A, Nowak D,. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir. Med. 1998; 92: 609-23.
6. Zafarullah M, Li WQ, Sylvester J, et al,. Molecular mechanisms of N-acetylcysteine actions. Cell. Mol. Life Sci. 2003; 60: 6-20.
7. Behr J, Maier K, Degenkolb B, et al,. Antioxidative and clinical effects of high-dose N-Acetylcysteine in fibrosing alveolitis: adjunctive therapy to maintenance immunosuppression. Am. J. Respir. Crit. Care Med. 1997; 156: 1897-901.
8. Meyer A, Buhl R, Magnussen H,. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur. Respir. J. 1994; 7: 431-6.
9. Meyer A, Buhl R, Kampf S, et al,. Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am. J. Respir. Crit. Care Med. 1995; 152: 1055-60.
10. Demedts M, Behr J, Buhl R, et al,. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353: 2229-42.
11. Bridgeman MME, Marsden M, Selby C, et al,. Effect of N-acetylcysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax 1994; 49: 670-5.
12. Cotgreave IA, Eklund A, Larsson K, et al,. No penetration of orally administered N-acetylcysteine into bronchoalveolar lavage fluid. Eur. J. Respir. Dis. 1987; 70: 73-7.
13. Hagiwara S, Ishii Y, Kitamura S,. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. Am. J. Respir. Crit. Care Med. 2000; 162: 225-31.
14. American Thoracic Society/European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment, international consensus statement. Am. J. Respir. Crit. Care Med. 2000; 161: 646-64.
15. Japanese Respiratory Society's Committee Formulating Diagnosis and Treatment Guideline for Diffuse Lung Diseases. Clinical Diagnostic and Treatment Guidance for Idiopathic Interstitial Pneumonias. Nankodo, Tokyo, 2004.
16. Raghu G, Mageto YN, Lockhart D, et al,. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study. Chest 1999; 116: 1168-74.
17. Nishimura K, Kitaichi M, Izumi T, et al,. Usual interstitial pneumonia: histologic correlation with high-resolution CT. Radiology 1992; 182: 337-42.
18. Yokoyama A, Kohno N, Hamada H, et al,. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1998; 158: 1680-4.
19. Takahashi H, Fujishima T, Koba H, et al,. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am. J. Respir. Crit. Care Med. 2000; 162: 1109-14.
20. Kohno N, Kyoizumi S, Awaya Y, et al,. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1999; 96: 68-73.
21. Kohno N, Awaya Y, Oyama T, et al,. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am. Rev. Respir. Dis. 1993; 148: 637-42.
22. Inoue Y, Barker E, Daniloff E, et al,. Pulmonary epithelial cell injury and alveolar-capillary permeability in berylliosis. Am. J. Respir. Crit. Care Med. 1997; 156: 109-15.
23. Flaherty K, Andrei AC, Murray S, et al,. Idiopathic pulmonary fibrosis. Prognostic value of changes in physiology and six-minute-walk test. Am. J. Respir. Crit. Care Med. 2006; 174: 803-9.
24. King TE Jr, Tooze JA, Schwarz MI, et al,. Predicting survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2001; 164: 1171-81.
25. Taniguchi H, Kataoka K, Kondoh Y, et al,. A questionnaire survey for revision of disease severity criteria of idiopathic pulmonary fibrosis in Japan. The Annual Report by Study Group of Ministry of Health and Welfare for Diffuse Lung Diseases 2010; 67-73.
26. Fletcher CM,. The clinical diagnosis of pulmonary emphysema; an experimental study. Proc. R. Soc. Med. 1952; 45: 577-84.
27. Chrystyn H, Ismail NE,. Relative bioavailability of salbutamol to the lungs following inhalation by three nebulised methods. Am. J. Respir. Crit. Care Med. 2004; 169: A311.
28. Dhand R, Duncan H, Hogue C,. Dose-response to albuterol administered with a new vibrating mesh nebulizer or MDI in patients with stable, mild to moderate asthma. Am. J. Respir. Crit. Care Med. 2004; 169: A315.
29. Muramatsu Y, Sugino K, Sato K, et al,. Efficacy of inhaled N-acetylcysteine on lung function and redox balance in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 183: A1529.
30. Investigators IPF,. The IPFnet strategyâcreating a comprehensive approach in the treatment of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2010; 181: 527-8.
31. Tomioka H, Kuwata Y, Imanaka K, et al,. A pilot study of aerosolized N-acetylcysteine for idiopathic pulmonary fibrosis. Respirology 2005; 10: 449-55.
32. Beeh KM, Beier J, Haas IC, et al,. Glutathione deficiency of the lower respiratory tract in patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 2002; 19: 1119-23.
33. Flaherty KR, Mumford JA, Murray S, et al,. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2003; 168: 543-8.
34. King TE Jr, Safrin S, Starko KM, et al,. Analyses of efficacy end points in a controlled trial of interferon-c1b for idiopathic pulmonary fibrosis. Chest 2005; 127: 171-7.
35. Latsi PI, du Bois RM, Nicholson AG, et al,. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am. J. Respir. Crit. Care Med. 2003; 168: 531-7.
36. Collard HR, King TE Jr, Bartelson BB, et al,. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168: 538-42.
37. Zappala CJ, Latsi PI, Nicholson AG, et al,. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010; 35: 830-5.